SAG
DFTX

SageView Advisory Group’s Definium Therapeutics DFTX Stock Holding History

SageView Advisory Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$81 Buy
+6
New +$74 ﹤0.01% 2552
2024
Q2 		– Sell
-2,648
Closed -$238K – 654
2024
Q1 		$238K Buy
+2,648
New +$15.1K 0.01% 475

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

SageView Advisory Group's DFTX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Definium Therapeutics (DFTX) in Q4 2025: 6 shares worth $81. The stake represents ﹤0.01% of the portfolio and ranks #2552 among its holdings. This is a return to the name: SageView Advisory Group previously reported a position in DFTX as recently as Q1 2024.

SageView Advisory Group first reported a position in DFTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $238K in Q1 2024. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

  • SageView Advisory Group held 6 shares of Definium Therapeutics worth $81 as of Q4 2025.
  • Definium Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Definium Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2552 holding.
  • SageView Advisory Group first reported a position in Definium Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • SageView Advisory Group's Definium Therapeutics position peaked at $238K in Q1 2024.
  • 208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.